NVCT
NASDAQNuvectis Pharma Inc.
Website
News25/Ratings4
News · 26 weeks23+100%
2025-10-262026-04-19
Mix690d
- SEC Filings4(67%)
- Offering1(17%)
- Other1(17%)
Latest news
25 items- PRNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research MeetingFort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2026 American Association for Cancer Research Meeting (2026 AACR), taking place from April 17th to April 22nd in San Diego, CA. Abstract TitlePoster Presentation DetailsNXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC modelsSession TitleCombina
- SECSEC Form EFFECT filed by Nuvectis Pharma Inc.EFFECT - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECSEC Form S-3 filed by Nuvectis Pharma Inc.S-3 - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECSEC Form 10-K filed by Nuvectis Pharma Inc.10-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma, Inc. Reports 2025 Financial Results and Business HighlightsFORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2025 was an eventful year for Nuvectis, with significant progress made in the NXP900 development program, laying the groundwork for multiple potential data readouts in 2026. Our Phase 1b monotherapy s
- INSIDERChief Dev. & Ops. Officer Shemesh Shay was granted 150,000 shares, increasing direct ownership by 9% to 1,793,068 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERChairman & CEO Bentsur Ron was granted 150,000 shares, increasing direct ownership by 4% to 3,675,924 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERChief Science & Business Off Poradosu Enrique was granted 150,000 shares, increasing direct ownership by 9% to 1,806,319 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERVice President, Finance Carson Michael J. was granted 61,200 shares, increasing direct ownership by 44% to 200,118 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- PRNuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLCFort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osimertinib is Tagrisso®, marketed by Astra Zeneca. Tagrisso, a 3rd generation EGFR inhibitor is broadly used in patients with NSCLCmut+ as single agent or in combination with chemotherapy a
- PRNuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLCFort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT, the "Company")), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, including the combination with osimertinib in non-small cell lung cancer. To register for the event, click here. The event will feature Alexander Spira, MD, PhD, FACP, FASCO (Chief Scientific Officer, NEXT Oncology) and Asier Unc
- INSIDERChairman & CEO Bentsur Ron bought $28,600 worth of shares (5,000 units at $5.72), increasing direct ownership by 0.14% to 3,525,924 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERDirector Sanchez Juan bought $75,270 worth of shares (13,000 units at $5.79), increasing direct ownership by 20% to 78,150 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERDirector Kaplan Matthew L. bought $64,240 worth of shares (11,000 units at $5.84), increasing direct ownership by 10% to 124,760 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRCORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsFORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ:NVCT), the tables were not included. The tables have been added and the corrected release follows: NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-endNXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dos
- SECSEC Form 10-Q filed by Nuvectis Pharma Inc.10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsNXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-endNXP900 Phase 1a dose escalation study successfully completed highlighting robust pharmacodynamic responses at clinically relevant doses facilitating once-daily oral dosingNXP900 clinical drug-drug interaction study in healthy volunteers successfully completed supporting our strategy for combination therapyPoster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics high
- INSIDERDirector Sanchez Juan was granted 30,000 shares, increasing direct ownership by 85% to 65,150 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERNew insider Sanchez Juan claimed ownership of 35,565 shares (SEC Form 3)3 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERLarge owner Mosseri Marlio Charles bought $957,083 worth of shares (154,770 units at $6.18) (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- PRNuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsFort Lee, NJ, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided highlights for NXP900 poster presentations that took place last week at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "The results from the Phase1a dose escalation and clinical drug-drug interaction studies are important building blocks in NXP900's clinical development journey to
- PRNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsFort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming poster presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA. Titles and PresentersPresentation DetailsTitle Clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions for the SRC/YES1 kinase inhibitor NXP900Presenter Gerald Falchook, MD Sarah Cannon Researc
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)